ZeroStack Corp., through its subsidiary, Phatebo GmbH, engages in the pharmaceutical distribution business in Germany. It operates through Commercial & Wholesale and ...
ZeroStack Corp. (NASDAQ: ZSTK) is a public company incorporated in 2019 and headquartered in Toronto, Canada (website: https://zerostack.ai). The company describes itself as both (1) a decentralized AI treasury / AI-focused asset management platform and (2) an operator in commercial and wholesale pharmaceutical distribution in Germany through its subsidiary Phatebo GmbH.
From a business-model perspective, ZeroStack’s AI-focused strategy centers on allocating capital to the ecosystem supporting AI infrastructure. According to the provided company description, it pursues this theme through strategic ownership of 0G tokens and by investing in early-stage companies. This positions the firm in the “asset management / financial services” category, where the core value proposition is gaining exposure to AI infrastructure development via crypto/technology-related holdings and investments.
In parallel, ZeroStack also runs a more traditional distribution business. Through Phatebo GmbH, it distributes a range of pharmaceutical goods and medical products across health indications (including areas such as cancer therapies, ADHD, multiple sclerosis, and anti-depressants, as stated in the provided materials). This creates a diversified operating footprint: one side is tied to regulated distribution and wholesale logistics in Germany, while the other side is oriented toward investments and token-based exposure related to AI infrastructure.
In terms of scale and operations, the provided data indicates a relatively small workforce (about 21 full-time employees), which aligns with the company size band of roughly 11–50 employees. As a result, the company likely relies on specialized partners, subsidiaries, and contracted resources to run both the distribution operations and the investment/treasury activities.
Cost, BOM, and financials: the provided dataset includes numerous TTM financial ratios (e.g., margins, cash-flow-related metrics, and liquidity/coverage ratios) showing negative profitability and cash-flow measures typical of early-stage or investment-heavy models. While the specific line items are not reproduced here, the overall picture is consistent with a company balancing operating expenses, investment activity, and potential scale-up costs across both business segments.
Key people: the provided sources identify Daniel Reis Faria as CEO and co-founder (with additional references noting leadership changes in prior periods). The company’s strategic direction is therefore closely tied to its leadership’s focus on both AI infrastructure exposure and the operational execution of the subsidiary distribution business.
Finally, the company has undergone branding/corporate history changes: it was formerly known as Flora Growth Corp. and changed its name to ZeroStack Corp. in January 2026, reflecting a shift toward its current AI/treasury narrative and public-market identity.
EU Pharmaceutical Manufacturers (Various - Suppliers to Phatebo GmbH)Zero Gravity Labs Inc. (0G Labs)Franchise Global Health & Wellness GmbHHack VC (Lead Investor in 0G Labs Seed Round)
Downstream
4
Major Pharmaceutical Company (Unnamed - $6.5M German Distribution Order)German Pharmacies & Hospitals (via Phatebo Distribution Network)Sunshine State Distributing LLCUnited Beverage Distribution Inc.
